Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01515566 · ClinicalTrials.gov registry record · Phase 1
Breakthrough Dyspnea Fentanyl Study in Cancer Patients
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT01515566: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT01515566 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 26 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01515566, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if fentanyl given under the skin can reduce shortness of breath in cancer patients. Researchers also want to learn if it can help to improve your physical function. In this study, fentanyl will be compared to a placebo. Fentanyl is commonly used for treatment of cancer pain. It is believed to help patients with their shortness of breath as well. A placebo is not a drug. It looks like the study drug but is not designed to treat any disease or illness. It is designed to be compared with a study drug to learn if the study drug has any real effect.
Interventions
- OTHER Placebo
- BEHAVIORAL Questionnaires
- DRUG Fentanyl
- OTHER Walking Tests
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2012-04 |
| Est. Completion | 2013-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01515566
The ClinicalTrials.gov registry entry for NCT01515566 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01515566 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01515566 about?
NCT01515566 is a clinical study titled "Breakthrough Dyspnea Fentanyl Study in Cancer Patients". The goal of this clinical research study is to learn if fentanyl given under the skin can reduce shortness of breath in cancer patients. Researchers also want to learn if it can help to improve your physical function. In this study, fentanyl will be compared to a placebo. Fentanyl is commonly used ...
What is the current status of trial NCT01515566?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2012-04. Estimated completion is 2013-04.
What interventions are being tested in trial NCT01515566?
The interventions under investigation include: Placebo (OTHER), Questionnaires (BEHAVIORAL), Fentanyl (DRUG), Walking Tests (OTHER).
Who is sponsoring clinical trial NCT01515566?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.